Tags

Type your tag names separated by a space and hit enter

Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
Clin Cancer Res. 2003 Oct 01; 9(12):4627-35.CC

Abstract

PURPOSE

The peroxisome proliferator-activated receptor-gamma (PPARgamma), a ligand-dependent transcription factor belonging to the family of nuclear receptors, has been implicated in the control of cyclooxygenase (COX) 2 expression in some tissue, although the exact mechanism(s) of this activity has not been elucidated. In this study we explored the possible mechanism(s) of control of COX-2 gene expression through PPARgamma signaling in human cervical cancer.

EXPERIMENTAL DESIGN

Using primary human cervical tissues and the CaSki human cervical cancer cell line, we assayed for PPARgamma and COX-2 mRNA expression by reverse transcription-PCR. Nuclear protein binding activities to three response elements located in the COX-2 promoter [nuclear factor kappaB (NFkappaB), cyclic AMP response element, and activator protein (AP)-2] were measured by gel mobility shift assays. We used transient transfection assays with COX-2 promoter reporter gene constructs to determine the regulatory sites in this promoter, which mediates PPARgamma regulation of COX-2 activity.

RESULTS

We showed, for the first time, that primary human cervical cancer tissues express PPARgamma. Using CaSki cells, we demonstrated that COX-2 and PPARgamma mRNA levels were inversely regulated by PPARgamma ligands in that these compounds up-regulated PPARgamma but down-regulated COX-2. In contrast, epidermal growth factor (EGF), a potent activator of COX-2, decreased PPARgamma mRNA levels. This down-regulation of PPARgamma mRNA by EGF was blocked in the presence of NS-398, a selective COX-2 inhibitor. PPARgamma ligands suppressed the binding activities of AP-1 (binding to CRE) and NFkappaB but not AP-2. Transient transfection results indicated that EGF stimulated whereas PPARgamma ligands inhibited COX-2 promoter (-327/+59) activity. This effect by PPARgamma ligands on the COX-2 promoter was blocked when the CRE, but not the NFkappaB, binding site was mutagenized.

CONCLUSION

Cervical cancer cells express readily detectable levels of PPARgamma. There is reciprocal negative regulation between COX-2 and PPARgamma signaling in human cervical cancer cells. The ability of PPARgamma ligands to inhibit COX-2 appears to be mediated predominantly through inhibition of AP-1 protein binding to the CRE site in the COX-2 promoter.

Authors+Show Affiliations

Division of Research, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14555539

Citation

Han, Shouwei, et al. "Control of COX-2 Gene Expression Through Peroxisome Proliferator-activated Receptor Gamma in Human Cervical Cancer Cells." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 9, no. 12, 2003, pp. 4627-35.
Han S, Inoue H, Flowers LC, et al. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res. 2003;9(12):4627-35.
Han, S., Inoue, H., Flowers, L. C., & Sidell, N. (2003). Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 9(12), 4627-35.
Han S, et al. Control of COX-2 Gene Expression Through Peroxisome Proliferator-activated Receptor Gamma in Human Cervical Cancer Cells. Clin Cancer Res. 2003 Oct 1;9(12):4627-35. PubMed PMID: 14555539.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. AU - Han,Shouwei, AU - Inoue,Hiroyasu, AU - Flowers,Lisa C, AU - Sidell,Neil, PY - 2003/10/14/pubmed PY - 2004/5/21/medline PY - 2003/10/14/entrez SP - 4627 EP - 35 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin. Cancer Res. VL - 9 IS - 12 N2 - PURPOSE: The peroxisome proliferator-activated receptor-gamma (PPARgamma), a ligand-dependent transcription factor belonging to the family of nuclear receptors, has been implicated in the control of cyclooxygenase (COX) 2 expression in some tissue, although the exact mechanism(s) of this activity has not been elucidated. In this study we explored the possible mechanism(s) of control of COX-2 gene expression through PPARgamma signaling in human cervical cancer. EXPERIMENTAL DESIGN: Using primary human cervical tissues and the CaSki human cervical cancer cell line, we assayed for PPARgamma and COX-2 mRNA expression by reverse transcription-PCR. Nuclear protein binding activities to three response elements located in the COX-2 promoter [nuclear factor kappaB (NFkappaB), cyclic AMP response element, and activator protein (AP)-2] were measured by gel mobility shift assays. We used transient transfection assays with COX-2 promoter reporter gene constructs to determine the regulatory sites in this promoter, which mediates PPARgamma regulation of COX-2 activity. RESULTS: We showed, for the first time, that primary human cervical cancer tissues express PPARgamma. Using CaSki cells, we demonstrated that COX-2 and PPARgamma mRNA levels were inversely regulated by PPARgamma ligands in that these compounds up-regulated PPARgamma but down-regulated COX-2. In contrast, epidermal growth factor (EGF), a potent activator of COX-2, decreased PPARgamma mRNA levels. This down-regulation of PPARgamma mRNA by EGF was blocked in the presence of NS-398, a selective COX-2 inhibitor. PPARgamma ligands suppressed the binding activities of AP-1 (binding to CRE) and NFkappaB but not AP-2. Transient transfection results indicated that EGF stimulated whereas PPARgamma ligands inhibited COX-2 promoter (-327/+59) activity. This effect by PPARgamma ligands on the COX-2 promoter was blocked when the CRE, but not the NFkappaB, binding site was mutagenized. CONCLUSION: Cervical cancer cells express readily detectable levels of PPARgamma. There is reciprocal negative regulation between COX-2 and PPARgamma signaling in human cervical cancer cells. The ability of PPARgamma ligands to inhibit COX-2 appears to be mediated predominantly through inhibition of AP-1 protein binding to the CRE site in the COX-2 promoter. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/14555539/Control_of_COX_2_gene_expression_through_peroxisome_proliferator_activated_receptor_gamma_in_human_cervical_cancer_cells_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=14555539 DB - PRIME DP - Unbound Medicine ER -